Bristol Myers Squibb (BMS) reported full-year 2025 revenue of $48.2 billion, which is almost the same as $48.3 billion in 2024[1]. BMS-attributable net income came in at $7.1 billion, or $3.46 per share, on a GAAP basis, versus a loss of $8.9 billion in 2024[1]. On a non-GAAP basis, net income was $12.5 billion, or $6.15 per share, up from $2.3 billion in the prior year[1]. In the fourth quarter of 2025, revenues rose 1% to $12.5 billion and Growth Portfolio revenues increased 16% to $7.4 billion[1]. Fourth quarter GAAP EPS was $0.53 and non-GAAP EPS was $1.26[1]. The company provided 2026 guidance of approximately $46.0 billion to $47.5 billion in revenue and non-GAAP EPS of $6.05 to $6.35[1]. Additionally, it increased its quarterly dividend to $0.63 per share, its 17th consecutive increase[1].